c-Ret

Inhibitory Selectivity
Catalog No.Inhibitor Name c-RETOther
A10250Regorafenib
****
Raf-1,VEGFR2,Kit
A10715Danusertib
**
Aurora A,Abl,TrkA
A11180TG101209
***
JAK2,FLT3,JAK3
A13832RPI-1
*

Notes:
1.Hover mouse over " * " to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of " * " is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.



5 Item(s)

per page

Set Descending Direction
Catalog No. Product Name Application Product Information
A10250 SALE

Regorafenib (BAY 73-4506)

VEGFR inhibitor
Regorafenib (BAY 73-4506) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf. Regorafenib (BAY 73-4506) is an orally bioavailable multikinase inhibitor targeting both the tumor and its vasculature.
A10715 SALE

Danusertib (PHA-739358)

Aurora inhibitor
Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. Phase 2
A11180

TG101209

JAK2 inhibitor

TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells.

A13832 SALE

RPI-1

Ret kinase inhibitor
RPI-1 is a competitive, potent ATP-dependent Ret kinase inhibitor.
A15218

Regorafenib monohydrate

Tyrosine kinase inhibitor
Regorafenib is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively.

5 Item(s)

per page

Set Descending Direction